التفاصيل البيبلوغرافية
| العنوان: |
Continuous tenecteplase infusion combined with peri/postprocedural platelet glycoprotein IIb/IIIa inhibition in peripheral arterial thrombolysis: initial safety and feasibility experience. |
| المؤلفون: |
Allie, David E., Hebert, Chris J., Lirtzman, Mitchell D., Wyatt, Charles H., Keller, Antoine, Khan, Mohamed H., Khan, Muhammad A., Fail, Peter S., Stagg Jr., Samuel J., Chaisson, Gary A., Vitrella, Dennis A., Allie, Sonja D., Allie, Adam A., Mitran, Elena V., Walker, Craig M., Keller, V Antoine, Stagg, Samuel J |
| المصدر: |
Journal of Endovascular Therapy; Aug2004, Vol. 11 Issue 4, p427-435, 9p, 2 Color Photographs, 4 Charts |
| مصطلحات موضوعية: |
THROMBOLYTIC therapy, GLYCOPROTEINS, ARTERIAL diseases, PHARMACOLOGY, DRUG side effects |
| مستخلص: |
Purpose: To evaluate a continuous-infusion protocol for peripheral arterial thrombolysis using tenecteplase (TNK), with regard to the technique, dosing, infusion times, and clinical outcomes.Methods: Between November 1999 and July 2002, 48 patients (30 men; mean age 68.5+/-11.9 years) presented with acute limb ischemia (ALI) owing to iliofemoral arterial thrombosis, which was treated with continuous TNK infusion (either 0.50 mg/h [n=22, group A] or 0.25 mg/h [n=26, group B]). All patients received periprocedural heparin (500 U/h) and peri and postprocedural tirofiban for 6 to 12 hours. Follow-up included ankle-brachial index and duplex ultrasound at baseline, 1 month, and 6 months. The variables retrospectively analyzed included total infusion time, total TNK dose, fibrinogen analysis, clinical and thrombolysis outcomes, and complications.Results: The overall clinical procedural success was 95.8%. Complete (>95%) lysis was observed in 35 (73%) patients; overall mean infusion time was 7.5 hours, and overall mean TNK dose was 4.8 mg. No deaths, intracranial bleeding, or embolic events occurred in either group. Of the 8 (16.7%) complications, 5 (10.4%) were major: 1 femoral repair (group A), 2 >5-cm nonsurgical hematomas (1 in each group), and 2 gastrointestinal hemorrhages (1 in each group). The 3 (6.3%) minor complications were minor hematomas (2 in group A and 1 in group B). The 30-day and 14-month mean limb salvage rates were 95.8% (46/ 48) and 89.6% (43/48), respectively.Conclusions: Continuous TNK infusion (0.25-0.50 mg/h) is a safe and feasible treatment for continuous pharmacological thrombolysis in ALI, potentially offering decreased infusion times and bleeding complications, as well as improved outcomes. [ABSTRACT FROM AUTHOR] |
|
Copyright of Journal of Endovascular Therapy is the property of Sage Publications Inc. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
